Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Undergoing Standard of Care Chemo-immune Checkpoint Inhibitor -Therapy: a Phase II, Multicenter, Randomized and Controlled

The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of chemotherapy (gemcitabine and cisplatin) plus durvalumab (immune-checkpoint-inhibitor, ICI). The main question it aims to answer is whether it is safe to combine chemotherapy (gemcitabine and cisplatin) and immunotherapy (durvalumab) - CICI therapy.
Participants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and CICI, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined.
Researchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate.

开始日期2025-06-01

申办/合作机构

Insel Gruppe AG

[+1]

NCT05700448

/ Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2025-06-01

申办/合作机构

基石药业（苏州）有限公司

NCT06622057

/ Not yet recruiting临床3期

Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).
Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.

开始日期2025-04-01

申办/合作机构

因华生技制药股份有限公司

100 项与吉西他滨相关的临床结果

登录后查看更多信息

100 项与吉西他滨相关的转化医学

登录后查看更多信息

100 项与吉西他滨相关的专利（医药）

登录后查看更多信息

20,220

项与吉西他滨相关的文献（医药）

2025-12-01·Journal of Gastrointestinal Cancer

Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)

Article

作者: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma

INTRODUCTION:

Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.

MATERIALS AND METHODS:

Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m² to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.

RESULTS:

Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.

CONCLUSIONS:

Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.

2025-04-01·SURGERY

Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes

Article

作者: Ban, Daisuke ; Miyata, Akinori ; Esaki, Minoru ; Mizui, Takahiro ; Nara, Satoshi ; Takamoto, Takeshi

BACKGROUND:

With the advent of improved chemotherapy options, neoadjuvant chemotherapy has gained acceptance as a multidisciplinary treatment approach for localized pancreatic ductal adenocarcinoma. This study aimed to clarify whether neoadjuvant chemotherapy with gemcitabine and S-1 influences preoperative nutritional status and postoperative outcomes, particularly in patients undergoing highly invasive pancreatic resection.

METHODS:

Patients with resectable pancreatic ductal adenocarcinoma who underwent pancreaticoduodenectomy as upfront surgery or after neoadjuvant chemotherapy with gemcitabine and S-1 between January 2015 and December 2022 were assessed. In addition to perioperative surgical outcomes, preoperative nutritional status was evaluated using serum albumin, controlling nutritional status, and prognostic nutritional index.

RESULTS:

A total of 158 patients who underwent upfront pancreaticoduodenectomy and 119 who received neoadjuvant chemotherapy with gemcitabine and S-1 before pancreaticoduodenectomy were evaluated. Preoperative nutritional assessments (serum albumin, controlling nutritional status score, and prognostic nutritional index) showed no significant differences between groups, either at the initial consultation or immediately before surgery. No significant differences were observed in postoperative outcomes, including blood loss, operation time, and morbidity. The neoadjuvant chemotherapy with gemcitabine and S-1 group had a significantly greater rate of negative tumor margins (R0 resection rate 86% vs 74%, P = .018), and improved overall survival (hazard ratio, 0.41; 95% confidence interval, 0.25-0.67, P < .001) compared with the upfront pancreaticoduodenectomy group.

CONCLUSIONS:

Neoadjuvant chemotherapy with gemcitabine and S-1 does not adversely impact preoperative nutritional status and enhances the effectiveness of pancreaticoduodenectomy for resectable pancreatic ductal adenocarcinoma, leading to improved pathologically curative resection rates and overall survival.

2025-03-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Chemical and biological investigations on modified gemcitabine by nanoliposome structured on cholesterol, pectin, and phosphatidylcholine as an anticancer drug via a drug delivery system

Article

作者: Alamri, Saad A ; Mostafa, Yasser S ; El-Shafai, Nagi M ; Zaghloul, Asmaa ; Shukry, Mustafa ; Emira, Amal ; El-Mehasseb, Ibrahim

Gemcitabine hydrochloride (GEM) mimics one of the building blocks of DNA and RNA, so it indicates possible chemotherapeutic effects. It prevents cancer cells from producing DNA and proteins, which ultimately leads to their death. The goal of this work is to modify the GEM medication by nanoforming nanoliposomes based on the composition of Cholesterol, pectin nanoparticles, and phosphatidylcholine (PhC). The drug in nanoliposome form is made using the precipitation method, and several approaches are employed to characterize it. UV-Vis spectroscopy is used to measure the release process of GEM from the lipids and its integration with them. Results of the combination efficiency for PhC.Pectin@GEM, PhC.GEM@Pectin, and PhC@Cholestrol.GEM were recorded at 78.8 %, 83 %, and 80 %, respectively. A UV-Vis spectrophotometer was used to determine the release efficiency of the nanoliposomes, which was measured at pH values of 3, 6.8, and 7.4. The in-vitro investigation employed SRB (Routine analysis IC₅₀) to determine the modified drug's toxicity on breast adenocarcinoma (MCF-7) cells, while the in-vitro study assessed the produced nanoliposomes' capacity to do so. The conclusion is that to ascertain whether GEM medicine's nanoliposomes can effectively treat breast cancer in place of GEM medication, clinical trials are necessary to prove the ability for treatment.

2,027

项与吉西他滨相关的新闻（医药）

2025-01-16

·Business Wire

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

NEW YORK--( BUSINESS WIRE )-- PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new preclinical data for SIL-204, its next-generation siRNA candidate. These findings reaffirm the company’s innovative approach to addressing some of the most challenging cancers, including pancreatic cancer, which is marked by KRAS mutations in over 90% of cases. The newly released data reveal significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine. In human pancreatic tumor cell models harboring KRAS G12D mutations, SIL-204 amplified the efficacy of these standard therapies, resulting in greater reductions in cancer cell confluence compared to chemotherapy alone. This underscores SIL-204’s potential to enhance treatment regimens for pancreatic cancer and other KRAS-driven cancers, potentially addressing a substantial unmet medical need. Building on the success of its first-generation LODER™ platform, which improved overall survival in Phase 2 trials, SIL-204 takes Silexion’s RNAi approach further by targeting a broader spectrum of KRAS mutations. With toxicology studies set to begin soon and Phase 2/3 trials planned for 2026, Silexion remains on track to advance its groundbreaking candidate into the clinic. Shortly releasing this new data, Silexion also announced the pricing of a $5 million public offering to support its preclinical and clinical efforts. While this may introduce near-term dilution, if the offering is to close, the additional capital seems to bolster the company’s ability to drive innovation and achieve key clinical milestones as it moves forward. As KRAS-driven cancers continue to be among the most aggressive and elusive to treat, Silexion’s progress with SIL-204 positions it as an important innovator to watch in the precision oncology space, offering hope for transformative therapies that could redefine cancer care. Subscribe for more updates from PESG: https://www.pesgresearch.com/subscribe PESG is a commercial digital news and coverage brand. PESG’s market updates are intended to summarize news developments from issuers it engages with and thus include partner advertising content on behalf of the mentioned issuer [SLXN]. They are not intended to serve as financial or investment advice. Please see our full terms, disclaimers and compensation disclosures here : redditwire.com/terms. PESG is part of the Wall Street Wire network, which is operated by an IR provider for commercial purposes. Our content may include forward looking statements about the significance or impact an announcement or development may have on the future of a company or industry as well as other similar statements which may not come to fruition. We advise all readers refer to our full terms in the above link.

临床2期siRNA

2025-01-16

·凯莱英药闻

信达生物：靶向CLDN 18.2 ADC纳入突破性治疗药物品种，用于治疗晚期胰腺导管腺癌

欢迎关注凯莱英药闻今日，信达生物宣布，公司IBI343再次被中国国家药品监督管理局（NMPA）药品评审中心（CDE）纳入突破性治疗药物（BTD）品种名单，拟定适应症为至少接受过一种系统性治疗的CLDN18.2表达阳性的晚期胰腺导管腺癌。 IBI343是一款抗紧密连接蛋白18.2（CLDN18.2）抗体-依喜替康偶联物（ADC），目前处于III期临床阶段。该药物最早曾于2024年5月被CDE纳入BTD品种名单，用于至少接受过二种系统性治疗的CLDN18.2表达阳性的晚期胃/胃食管交界处腺癌。关于IBI343 IBI343是一款重组人源靶向CLDN18.2的ADC，与表达CLDN18.2的肿瘤细胞结合后，可发生CLDN18.2依赖性ADC内化，并释放毒素药物引起DNA损伤，导致肿瘤细胞凋亡。游离的毒素药物也可以通过质膜扩散到达并杀死相邻的肿瘤细胞，因此IBI343也具有“旁观者效应”。该药物在多种不同表达量的肿瘤细胞系上，展现了良好的Claudin 18.2特异性的体外杀伤活性，并在多种人源肿瘤异种移植小鼠模型上展现了良好的肿瘤抑制活性。基于糖基的定点偶联技术显著增强了整个ADC的稳定性。IBI343在恒河猴的GLP毒理实验中展现了良好的安全性，并在高至30 mg/kg的剂量下耐受性良好。 2024年6月，IBI343获美国食品和药物监督管理局（FDA）授予快速通道资格（FTD），拟用于至少接受过一种系统性治疗的CLDN18.2表达阳性的晚期胰腺导管腺癌。本次突破性治疗药物认定是基于一项正在中国、澳洲和美国进行的I期临床研究结果，该I期扩展队列的数据在2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia）大会上以口头形式报道。研究显示：该药物的整体疗效出色，患者mPFS 达到5.3 个月。在可评估的4 3 例患者中，ORR 为32.6%，cORR 为23.2%，cDCR 为81.4%，mDOR 为7.0（4.0-NC）个月，6个月DOR 率为63%，mPFS 为5.3（4.1- 7. 4）个月。公司此前已在2024 ASCO 首次报道的小样本数据，在10 名胰腺胆管腺癌患者中，未确认ORR 为40%。本次更新扩大样本数据与此前相当，且新增cORR 及PFS 数据。安全性上，三级以上胃肠道不良反应事件为0。在所有患者中，常见的不良反应为贫血、中性粒细胞计数减少、食欲下降、恶心和白细胞计数减少。51.2%的受试者发生≥3 级TEAE，其中≥3 级恶心、呕吐发生率均为0。关于靶向CLDN18.2的ADC CLDN18.2属于CLDNs家族成员，属于CLDNs18的亚型，它是一种CD20样分化的蛋白，尽管在正常组织中表达高度受限，在多种原发性恶性肿瘤发生发展过程中往往出现异常高表达。最初，其被发现能持续、稳定地高表达于多种胃癌组织，但随后研究表明，其也能在乳腺癌、结肠癌、肝癌、头颈癌、支气管癌以及非小细胞肺癌等多种原发恶性肿瘤中异常激活和过度表达，尤其好发于消化系统恶性肿瘤，包括胃癌（70%），胰腺癌（50％），食管癌（30％）等。预计2025-2035 年，美国和中国CLDN18.2抗体市场规模将分别从2.52 亿美元、2.00 亿美元增长至40.36 亿美元、37.44 亿美元，CAGR分别为32.0%、33.5%；其中，胃癌将贡献主要市场增量，2025-2035 年美国和中国CLDN18.2 抗体在胃癌领域市场规模将分别从0.65 亿美元、1.33 亿美元增长至10.87亿美元、24.03 亿美元，CAGR 分别为32.5%、33.6%。美国和中国CLDN18.2 抗体市场规模（亿美元）据不完全统计，目前在研的CLDN18.2约百余种，仅安斯泰来的佐妥昔单抗一款药物获批，研究种类主要包括ADC、CAR-T、双抗、单抗；由于CLDN18.2在特定肿瘤组织中具备高度选择性并稳定表达，同时在健康组织中表达受限，因此其逐渐作为开发癌症ADC 疗法的理想靶标。目前全球尚无已上市靶向CLDN18.2 ADC 药物, 除信达外，以国内企业礼新、康诺亚/乐普、恒瑞、德琪、荣昌、科伦博泰、信诺维等研发势头最强。关于胰腺癌胰腺癌是当前世界范围内死亡率最接近发病率的恶性肿瘤，恶性度高，进展快，转移早，预后差，因此被称为“癌症之王”。据GCO 统计，2022 年国内胰腺癌年新发约11.9 万人，死亡达10.6 万人。常见胰腺癌主要由于外分泌细胞形成，其中胰腺导管癌（PDAC）占比约80%。目前，晚期1L 治疗方案仍旧比较有限，多采用以氟尿嘧啶（5-FU）或吉西他滨为基础的化疗方案。二线治疗中，临床选择更加有限，无法为患者带来显著的临床获益，目前mPF S 普遍在2-3.5 个月左右， mOS 在6 个月左右。三线治疗中，目前报道的5-FU+LV+Na l-IRI 联合疗法及CBP501+cisplatin+n ivolu mab 疗法mPFS 均为1.9 个月。因此，胰腺癌2/ 3 线治疗存较大未满足临床需求。胰腺癌疗效整理对比关于信达生物信达生物成立于2011年，致力于开发、生产和销售肿瘤、代谢及心血管、自身免疫、眼科等重大疾病领域的创新药物。公司已有13款产品获得批准上市，同时还有4个品种在NMPA审评中，3个新药分子进入III期或关键性临床研究，另外还有17个新药品种已进入临床研究。近年来，公司与国内外众多知名企业和科研院，包括礼来、罗氏、赛诺菲、Adimab、Incyte和MD Anderson等国际合作方达成30多项战略合作。参考资料 1、公司官网 2、中信建投感谢关注、转发，转载授权、加行业交流群，请加管理员微信号“hxsjjf1618”。 “在看”点一下

突破性疗法临床结果临床1期ASCO会议抗体药物偶联物

2025-01-16

·药研网

信达生物：CLDN18.2ADC获CDE纳入突破性治疗药物品种

1月16日, 信达生物宣布其抗紧密连接蛋白18.2（CLDN18.2）抗体-依喜替康偶联物（ADC）IBI343已被CDE纳入突破性治疗药物（BTD）品种名单，拟定适应症为至少接受过一种系统性治疗的CLDN18.2表达阳性的晚期胰腺导管腺癌。本次突破性治疗药物认定是基于一项正在中国、澳洲和美国进行的I期临床研究结果（NCT05458219），IBI343单药在晚期胰腺导管腺癌患者中显示了令人鼓舞的疗效和良好的耐受性。该I期扩展队列的数据在2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia）大会上口头形式报道：共43例CLDN18.2阳性（定义为≥60%肿瘤细胞中CLDN18.2染色强度≥1+）晚期胰腺癌受试者接受IBI343 6 mg/kg Q3W治疗，所有受试者既往均接受至少1线治疗，60.5%的受试者既往接受过2线及以上的抗肿瘤治疗。确认的客观缓解率（ORR）为 23.3%，截至数据截止日期，26例受试者发生PFS事件，中位PFS为5.3 (4.1-7.4)月。 2024年5月，IBI343首个适应症获CDE纳入突破性治疗药物，为至少接受过二种系统性治疗的CLDN18.2表达阳性的晚期胃/胃食管交界处腺癌。 2024年6月，IBI343获得美国FDA授予快速通道资格（fast track designation, FTD），拟定适应症为至少接受过一种系统性治疗的CLDN18.2表达阳性的晚期胰腺导管腺癌。目前，IBI343已启动美国临床I期入组并于2024年12月完成首例受试者给药。胰腺癌是消化系统恶性程度最高的肿瘤之一，5年生存率约10%。近年来，胰腺癌发病率逐年升高，但早期诊断率极低，严重危害人类生命健康。目前，晚期胰腺癌治疗仍以系统性化疗为基础，一线治疗方案多采用以氟尿嘧啶（5-FU）或吉西他滨为基础的化疗方案。而在二线治疗中，临床选择十分有限，化疗响应率仅为6-16%，中位无进展生存期约2~5个月，中位生存期大约6~9个月ii，存在亟待满足的临床需求。胃癌和胰腺癌等肿瘤的靶向治疗手段较匮乏，存在巨大的未满足的临床需求。CLDN18.2高表达于胃癌和胰腺癌中，靶向CLDN18.2的药物是潜在的新型抗肿瘤治疗方案。目前为止，全球20多家药企布局了claudin 18.2靶向药物的临床开发，大部分在研项目属于单靶点抗体药物，此外还包括claudin 18.2双抗药物、ADC和CAR-T等。目前CLDN18.2靶点进入临床阶段的重点CLDN18.2 ADC产品有10余款，其中进入III期临床的有信达生物IBI-343、礼新医药LM-302、阿斯利康CMG-901、恒瑞医药SHR-A1904。吉满生物根据市场需求和研究现状，推出构建CLDN18.2表达稳定细胞系的服务，可用于抗体筛选、表征、一致性评价, 充分满足药物研发的需求，助力抗体药物临床申报（咨询吉满客服联系同微信：18916119826）。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载/商务/投稿 | 联系微信15618157102（sum_Gmi）商务合作稿件征集点击了解详情往期回顾 1 10月 | 20家生物医药裁员汇总 2 国产首款四价HPV疫苗拟纳入优先审评 3 3. 7亿美元!今年规模最大的生物医药融资诞生

突破性疗法抗体药物偶联物临床1期临床结果免疫疗法

100 项与吉西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02368	吉西他滨	L01BC05	DB00441

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性胆道肿瘤	临床3期	中国	AstraZeneca AB	2024-08-12
HER2阳性胆道肿瘤	临床3期	日本	AstraZeneca AB	2024-08-12
HER2阳性胆道肿瘤	临床3期	巴西	AstraZeneca AB	2024-08-12
HER2阳性胆道肿瘤	临床3期	中国台湾	AstraZeneca AB	2024-08-12
胰腺癌	临床3期	-	RenovoRx, Inc.	2023-06-01
转移性胰腺导管腺癌	临床3期	澳大利亚	Panbela Therapeutics, Inc.	2022-08-04
局部晚期胰腺腺癌	临床3期	美国	RenovoRx, Inc.	2018-03-12
局部晚期胰腺腺癌	临床3期	比利时	RenovoRx, Inc.	2018-03-12
晚期鳞状细胞肺癌	临床3期	美国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	比利时	Sanofi	2010-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Glofitamab with Gemcitabine and Oxaliplatin	夢積構鬱艱鑰積衊鹹願(鏇遞蓋繭構構夢糧願壓) = 築積糧窪憲網積鬱願鏇範積憲鹹鹽餘鹹蓋範觸 (艱構鹹蓋艱鏇鹽糧艱艱, NA) 更多	-	2024-12-09
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Rituximab with Gemcitabine and Oxaliplatin	夢積構鬱艱鑰積衊鹹願(鏇遞蓋繭構構夢糧願壓) = 鏇醖衊蓋選築積鏇選鏇範積憲鹹鹽餘鹹蓋範觸 (艱構鹹蓋艱鏇鹽糧艱艱, NA) 更多	-	2024-12-09
ASH2024	N/A	典型霍奇金淋巴瘤	-	Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD)	獵醖構衊鹹選醖繭製襯(壓糧顧鬱觸簾壓築廠衊) = 願遞夢獵鹽獵醖鬱願簾膚憲鹽艱鹽繭網糧蓋壓 (衊糧衊構繭鏇襯顧簾網 ) 更多	-	2024-12-09
ASH2024	N/A	难治性霍奇金淋巴瘤	-	Pembrolizumab Maintenance	衊窪襯築鬱獵膚鏇鏇糧(餘衊餘夢窪範鏇衊觸築) = 膚壓餘顧鹽淵製窪襯鹽窪遞糧糧鹽廠壓蓋構範 (膚願鬱繭蓋糧網鹹製範, 33 ~ 80)	-	2024-12-08
ASH2024	N/A	外周T细胞淋巴瘤	-	Lipo-MIT	築簾獵選糧鹽鑰築鑰築(艱積齋餘範製窪淵鏇鹹) = neutropenia (66.7%), leucopenia (44.4%), anaemia (33.3%) and thrombocytopenia (11.1%) 顧壓鹹餘繭艱範願選觸 (壓構鹹壓顧壓醖醖鏇夢 )	-	2024-12-07
ASH2024	N/A	复发性弥漫性大B细胞淋巴瘤	-	R-GemOx	鬱膚餘繭範壓網製膚簾(廠觸淵範鹽艱夢簾鏇衊) = 鏇艱構淵遞觸獵衊廠醖願膚襯願襯選網醖構範 (鏇醖選鏇獵襯醖壓蓋憲, 16‒29) 更多	-	2024-12-07
NCT04989218 (ICC, CTgov)	临床1/2期	肝内胆管癌	1	Tremelimumab+Gemcitabine+Cisplatin+Durvalumab	遞艱夢膚艱製遞餘窪遞(鏇廠醖醖廠製積艱壓願) = 鹽淵廠鏇糧淵鬱鬱遞艱願襯製製廠範顧製廠遞 (鏇簾齋遞壓淵醖廠鑰範, 築構範觸餘觸鏇觸壓壓 ~ 顧願蓋簾獵鬱觸構廠廠) 更多	-	2024-11-05
ASTRO2024	N/A	肌层浸润性膀胱癌	29	Bladder Only Gemcitabine Radiotherapy	衊壓膚製構積製製壓淵(積繭積餘壓築鑰衊鑰夢) = 餘顧蓋齋積窪願構鹹壓憲夢艱鹽鏇構簾鑰襯餘 (壓範築網製襯鑰顧築鑰 ) 更多	-	2024-10-01
NCT05026905 (TCOG T5221, ESMO2024) 人工标引	临床2期	胰腺癌一线	50	GASL (Gemcitabine plus nab-paclitaxel and S-1/leucovorin	壓醖顧顧製製鏇觸夢餘(積鹹蓋網顧觸糧願窪憲) = 構製醖襯壓積壓衊夢淵餘壓廠壓範壓糧簾鏇蓋 (鬱鑰憲襯憲齋選積觸襯 ) 更多	积极	2024-09-16
NCT05026905 (TCOG T5221, ESMO2024) 人工标引	临床2期	胰腺癌一线	50	GAP (Gemcitabine plus nab-paclitaxel and oxaliplatin)	壓醖顧顧製製鏇觸夢餘(積鹹蓋網顧觸糧願窪憲) = 窪壓蓋顧顧廠鬱淵膚製餘壓廠壓範壓糧簾鏇蓋 (鬱鑰憲襯憲齋選積觸襯 ) 更多	积极	2024-09-16
ESMO2024	N/A	胰腺癌辅助 lipopolysaccharide \| lipoteichoic acid	342	Adjuvant gemcitabine-based chemotherapy	範願鹹網鏇鹽構鑰艱觸(醖觸餘醖糧網鑰醖糧膚) = 膚鏇繭廠顧蓋遞襯繭積膚鹽觸齋壓構構網衊願 (繭顧選艱廠夢網範簾鹹 ) 更多	积极	2024-09-16
ESMO2024	N/A	胰腺癌辅助 lipopolysaccharide \| lipoteichoic acid	342	None / non-gemcitabine-based adjuvant chemotherapy	範願鹹網鏇鹽構鑰艱觸(醖觸餘醖糧網鑰醖糧膚) = 夢繭願獵網遞膚觸觸襯膚鹽觸齋壓構構網衊願 (繭顧選艱廠夢網範簾鹹 ) 更多	积极	2024-09-16
ESMO2024	N/A	转移性胰腺癌二线 CEA \| CA 19-9	260	Gemcitabine plus nab-paclitaxel	醖壓淵鑰選範範夢襯醖(淵淵鹽構簾廠餘選鑰製) = 鹹願鬱積網艱鹹膚憲積觸淵網鏇鹹構獵觸願網 (積鑰鹹築憲壓願窪膚醖, 5.6 ~ 7.1) 更多	积极	2024-09-16